Market Currents
Questcor's (QCOR -7.3%) early drubbing was apparently due to a mistaken headline stating that a...
-
Friday, November 2, 2012, 12:39 PM ETQuestcor's (QCOR -7.3%) early drubbing was apparently due to a mistaken headline stating that a synthetic version of Acthar had been approved by the FDA, rather than the Orphan Drug Designation it had actually been given, according to a Seeking Alpha contributor. The errant headline has since been pulled and refiled to reflect the correction, but the hangover in the shares continues in mid-day trading nontheless.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 6 comments:
As for the hangin' posse for the originator of the rumor - where did it start? When the stock was down 10% at 10:30 EST, I could only find one place that referenced it and that was Yahoo Financials. I kept my positions and went to bed noting that it was "not the end of the world" as Infantile Spasms comprise such a small portion of Acthar sales.
Lastly, I'm looking for a rebound tomorrow. However, if I don't see one I will have to assess whether or not I believe this stock can move confidently forward. The support sticks holding up this rock are crackin' and giving way a little to often for me.
I don't remember Questcor ever saying that someone couldn't spend 10 minutes filling out some paper work and filing it.
Obviously that research firm doesn't do research and doesn't understand the difference between being successfully approved vs filing paperwork.